All In Biotech

NDA 208169 · Btg Intl

Xuriden

Uridine Triacetate · Oral

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 2, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Sep 4, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

5

2 Phase 3, 0 recruiting

FAERS reports

48

28 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 18, 2025.

XURIDEN ® is indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria. XURIDEN is a pyrimidine analog for uridine replacement indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria. ( 1 )

Mechanism: Uridine triacetate is an acetylated form of uridine. Following oral administration, uridine triacetate is deacetylated by nonspecific esterases present throughout the body, yielding uridine in the circulation (Figure 1). Figure 1: Uridine Triacetate Conversion to Uridine XURIDEN provides uridine in the systemic circulation of patients with hereditary orotic aciduria who cannot synthesize adequate quantities of uridine due to a genetic defect in uridine nucleotide synthesis. Figure 1

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 2, 2019 Supplement 3 · Efficacy OrphanLetterLabel
  • Sep 4, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelSummary ReviewLetter
1 products under this application
  • XURIDEN · URIDINE TRIACETATE 2GM/PACKET · GRANULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Uridine Triacetate" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use11
  • diarrhoea4
  • foetal exposure during pregnancy4
  • low birth weight baby4
  • mucosal inflammation4
  • premature baby4
  • thrombocytopenia4
  • asthenia3
  • drug ineffective3
  • drug ineffective for unapproved indication3
  • dysphagia3
  • gastroenteritis3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
20165
20176
20182
20195
20204
20216
20221
20231
20243
20257
20267

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Btg Intl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.